PsiOxus Therapeutics Ltd. products

Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to unleash the power of the immune system, including genetically engineered cell therapies.